{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:25:37Z","timestamp":1777339537267,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eplepsyres.2022.107029","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:10:51Z","timestamp":1664453451000},"page":"107029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Extensive pharmacokinetic variability of Levetiracetam. \u00bfAre doctors aware?"],"prefix":"10.1016","volume":"187","author":[{"given":"Maria","family":"de Toledo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ferreiros-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Vieira Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Paula","family":"de Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Lagares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Sobrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Ovejero-Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2022.107029_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ane.13450","article-title":"Seizure freedom and plasma levels of newer generation antiseizure medications","volume":"144","author":"Aicua-Rapun","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FTD.0000000000000470","article-title":"Influence of comedication on levetiracetam pharmacokinetics","volume":"40","author":"Aldaz","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1186\/s12885-021-08443-x","article-title":"Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients","volume":"21","author":"Arshad","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2008.06.001","article-title":"Generic substitution in the treatment of epilepsy: patient and physician perceptions","volume":"13","author":"Berg","year":"2008","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pediatrneurol.2010.05.008","article-title":"Age and comedication influence levetiracetam pharmacokinetics in children","volume":"43","author":"Dahlin","year":"2010","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2021.11.022","article-title":"Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure","volume":"94","author":"Fluckiger","year":"2022","journal-title":"Seizure"},{"issue":"S1","key":"10.1016\/j.eplepsyres.2022.107029_bib8","first-page":"S31","article-title":"An analytical study to correlate serum levels of levetiracetam with clinical course in patients with epilepsy","volume":"7","author":"Gupta","year":"2016","journal-title":"J. Neurosci. Rural Pr."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib9","first-page":"826","article-title":"Levetiracetam therapeutic drug monitoring in a large cohort of Korean Epileptic patients","volume":"14","author":"Ha","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of age and comedication on levetiracetam pharmacokinetics and tolerability","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An updated overview on therapeutic drug monitoring of recent antiepileptic","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs Drugs R. D."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery\u2014pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","article-title":"Therapeutic drug monitoring of antiepileptic drugs: current status and future","volume":"16","author":"Johannessen Landmark","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/epi.16849","article-title":"The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results","volume":"62","author":"Johannessen Landmark","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/epi4.12239","article-title":"From clinical trials of antiepileptic drugs to treatment","volume":"3","author":"Perucca","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","article-title":"Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials","volume":"53","author":"Perucca","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2013.09.007","article-title":"Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010","volume":"23","author":"Pickrell","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/pharmaceutics12100943","article-title":"Pharmacokinetic monitoring of levetiracetam in Portuguese refractory epileptic patients: effect of gender, weight and concomitant therapy","volume":"12","author":"Silva","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.seizure.2018.09.004","article-title":"Review on the relevance of therapeutic drug monitoring of levetiracetam","volume":"62","author":"Sourbron","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2022.107029_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108284","article-title":"Pharmacokinetic variability of eslicarbazepine in real clinical practice","volume":"124","author":"de Toledo","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2022.107029_bib27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinicalpharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:47:45Z","timestamp":1760276865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122001802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":27,"alternative-id":["S0920121122001802"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107029","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive pharmacokinetic variability of Levetiracetam. \u00bfAre doctors aware?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107029"}}